BNGO vs. RPID, OMIC, HLTH, AXDX, TLIS, SEER, XAIR, DYAI, CLNN, and APLM
Should you be buying Bionano Genomics stock or one of its competitors? The main competitors of Bionano Genomics include Rapid Micro Biosystems (RPID), Singular Genomics Systems (OMIC), Cue Health (HLTH), Accelerate Diagnostics (AXDX), Talis Biomedical (TLIS), Seer (SEER), Beyond Air (XAIR), Dyadic International (DYAI), Clene (CLNN), and Apollomics (APLM). These companies are all part of the "medical" sector.
Bionano Genomics (NASDAQ:BNGO) and Rapid Micro Biosystems (NASDAQ:RPID) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings.
In the previous week, Bionano Genomics had 1 more articles in the media than Rapid Micro Biosystems. MarketBeat recorded 2 mentions for Bionano Genomics and 1 mentions for Rapid Micro Biosystems. Bionano Genomics' average media sentiment score of 0.03 beat Rapid Micro Biosystems' score of 0.00 indicating that Bionano Genomics is being referred to more favorably in the media.
Bionano Genomics received 157 more outperform votes than Rapid Micro Biosystems when rated by MarketBeat users. Likewise, 64.66% of users gave Bionano Genomics an outperform vote while only 26.67% of users gave Rapid Micro Biosystems an outperform vote.
Rapid Micro Biosystems has lower revenue, but higher earnings than Bionano Genomics. Rapid Micro Biosystems is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
Bionano Genomics has a beta of 2.33, indicating that its share price is 133% more volatile than the S&P 500. Comparatively, Rapid Micro Biosystems has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
Rapid Micro Biosystems has a net margin of -232.99% compared to Bionano Genomics' net margin of -643.74%. Rapid Micro Biosystems' return on equity of -39.02% beat Bionano Genomics' return on equity.
Bionano Genomics presently has a consensus target price of $21.33, indicating a potential upside of 2,613.82%. Given Bionano Genomics' higher possible upside, equities research analysts clearly believe Bionano Genomics is more favorable than Rapid Micro Biosystems.
11.4% of Bionano Genomics shares are owned by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are owned by institutional investors. 2.4% of Bionano Genomics shares are owned by insiders. Comparatively, 32.4% of Rapid Micro Biosystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Bionano Genomics beats Rapid Micro Biosystems on 9 of the 17 factors compared between the two stocks.
Get Bionano Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionano Genomics Competitors List
Related Companies and Tools
